Researchers developed ΨDNA, a DNA-based CRISPR guide that allows Cas12 enzymes to target RNA with high specificity while ...
Looking to one-up early stage entries in harnessing CRISPR technology, 2-year-old KSQ Therapeutics burst onto the biopharma scene with $76 million across two financing rounds and an aspiration to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results